Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer
Kyôko Hotta, R Tsuchiya(Tokyo National Hospital), T Kodama(National Cancer Center Hospital East), Ikuo Sekine(University of Tsukuba), Hisao Asamura(Keio University), Nobuyuki Yamamoto(National Cancer Center Hospital East), Yuichiro Ohe(National Cancer Center), Tomohide Tamura(St. Luke's International Hospital), Hideo Kunitoh(Japanese Red Cross Medical Center), K. Suzuki(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Nagahiro Saijo(National Cancer Center Hospital East), Hiroshi Kondo(Tokyo National Hospital)
Cited by 8
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835